journal
Journals Journal of Experimental & Clin...

Journal of Experimental & Clinical Cancer Research : CR

https://read.qxmd.com/read/38539232/analysis-of-the-effect-of-ccr7-on-the-microenvironment-of-mouse-oral-squamous-cell-carcinoma-by-single-cell-rna-sequencing-technology
#1
JOURNAL ARTICLE
Zengxu Wang, Keith L Kirkwood, Yao Wang, Weidong Du, Shanfeng Lin, Wanhang Zhou, Cong Yan, Jiaxing Gao, Zhenning Li, Changfu Sun, Fayu Liu
BACKGROUND: Studies have shown that CCR7, an important inflammatory factor, can promote the proliferation and metastasis of oral squamous cell carcinoma (OSCC), but its role in the tumor microenvironment (TME) remains unclear. This paper explores the role of CCR7 in the TME of OSCC. METHODS: In this work, we constructed CCR7 gene knockout mice and OSCC mouse models. Single-cell RNA sequencing (scRNA-seq) and bioinformatics were used to analyze the differences in the OSCC microenvironment between three CCR7 gene knockout mice (KO) and three wild-type mice (WT)...
March 27, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38532446/correction-a-glutamine-tug-of-war-between-cancer-and-immune-cells-recent-advances-in-unraveling-the-ongoing-battle
#2
Bolin Wang, Jinli Pei, Shengnan Xu, Jie Liu, Jinming Yu
No abstract text is available yet for this article.
March 26, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38532439/bispecific-aptamer-decorated-and-light-triggered-nanoparticles-targeting-tumor-and-stromal-cells-in-breast-cancer-derived-organoids-implications-for-precision-phototherapies
#3
JOURNAL ARTICLE
Simona Camorani, Alessandra Caliendo, Elena Morrone, Lisa Agnello, Matteo Martini, Monica Cantile, Margherita Cerrone, Antonella Zannetti, Massimo La Deda, Monica Fedele, Loredana Ricciardi, Laura Cerchia
BACKGROUND: Based on the established role of cancer-stroma cross-talk in tumor growth, progression and chemoresistance, targeting interactions between tumor cells and their stroma provides new therapeutic approaches. Dual-targeted nanotherapeutics selectively acting on both tumor and stromal cells may overcome the limits of tumor cell-targeting single-ligand nanomedicine due to the complexity of the tumor microenvironment. METHODS: Gold-core/silica-shell nanoparticles embedding a water-soluble iridium(III) complex as photosensitizer and luminescent probe (Iren -AuSiO2 _COOH) were efficiently decorated with amino-terminated EGFR (CL4) and PDGFRβ (Gint4...
March 26, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38528516/peli1-key-players-in-the-oncogenic-characteristics-of-pancreatic-cancer
#4
JOURNAL ARTICLE
Xiaobin Fei, Changhao Zhu, Peng Liu, Songbai Liu, Likun Ren, Rishang Lu, Junyi Hou, Yongjia Gao, Xing Wang, Yaozhen Pan
BACKGROUND: Pancreatic cancer (PC) is a highly malignant gastrointestinal tumor, which is characterized by difficulties in early diagnosis, early metastasis, limited therapeutic response and a grim prognosis. Therefore, it is imperative to explore potential therapeutic targets for PC. Currently, although the involvement of the Pellino E3 Ubiquitin Protein Ligase 1 (PELI1) in the human growth of some malignant tumors has been demonstrated, its association with PC remains uncertain. METHODS: Bioinformatics, qRT-PCR, Western blot and IHC were used to detect the expression of PELI1 in pancreas or PC tissues and cells at mRNA and protein levels...
March 25, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38523299/ropivacaine-as-a-novel-akt1-specific-inhibitor-regulates-the-stemness-of-breast-cancer
#5
JOURNAL ARTICLE
Lin Ding, Hui Jiang, Qiangwei Li, Qiushuang Li, Tian-Tian Zhang, Limeng Shang, Bin Xie, Yaling Zhu, Keshuo Ding, Xuanming Shi, Tao Zhu, Yong Zhu
BACKGROUND: Ropivacaine, a local anesthetic, exhibits anti-tumor effects in various cancer types. However, its specific functions and the molecular mechanisms involved in breast cancer cell stemness remain elusive. METHODS: The effects of ropivacaine on breast cancer stemness were investigated by in vitro and in vivo assays (i.e., FACs, MTT assay, mammosphere formation assay, transwell assays, western blot, and xenograft model). RNA-seq, bioinformatics analysis, Western blot, Luciferase reporter assay, and CHIP assay were used to explore the mechanistic roles of ropivacaine subsequently...
March 25, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38520004/cdkl1-potentiates-the-antitumor-efficacy-of-radioimmunotherapy-by-binding-to-transcription-factor-ybx1-and-blocking-pd-l1-expression-in-lung-cancer
#6
JOURNAL ARTICLE
Zixuan Li, Huichan Xue, Jinsong Li, Zhikun Zheng, Zhiwei Liu, Xiaorong Dong, Hongbo Wang, Jing Chen, Shuangbing Xu
BACKGROUND: The evasion of the immune response by tumor cells through programmed death-ligand 1 (PD-L1) has been identified as a factor contributing to resistance to radioimmunotherapy in lung cancer patients. However, the precise molecular mechanisms underlying the regulation of PD-L1 remain incompletely understood. This study aimed to investigate the role of cyclin-dependent kinase-like 1 (CDKL1) in the modulation of PD-L1 expression and the response to radioimmunotherapy in lung cancer...
March 22, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38515178/auranofin-repurposing-for-lung-and-pancreatic-cancer-low-ca12-expression-as-a-marker-of-sensitivity-in-patient-derived-organoids-with-potentiated-efficacy-by-akt-inhibition
#7
JOURNAL ARTICLE
Christophe Deben, Laurie Freire Boullosa, Felicia Rodrigues Fortes, Edgar Cardenas De La Hoz, Maxim Le Compte, Sofie Seghers, Marc Peeters, Steve Vanlanduit, Abraham Lin, Krijn K Dijkstra, Paul Van Schil, Jeroen M H Hendriks, Hans Prenen, Geert Roeyen, Filip Lardon, Evelien Smits
BACKGROUND: This study explores the repurposing of Auranofin (AF), an anti-rheumatic drug, for treating non-small cell lung cancer (NSCLC) adenocarcinoma and pancreatic ductal adenocarcinoma (PDAC). Drug repurposing in oncology offers a cost-effective and time-efficient approach to developing new cancer therapies. Our research focuses on evaluating AF's selective cytotoxicity against cancer cells, identifying RNAseq-based biomarkers to predict AF response, and finding the most effective co-therapeutic agents for combination with AF...
March 22, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38509571/cross-reactive-cd8-t-cell-responses-to-tumor-associated-antigens-taas-and-homologous-microbiota-derived-antigens-moas
#8
JOURNAL ARTICLE
Beatrice Cavalluzzo, Marie Christine Viuff, Siri Amanda Tvingsholm, Concetta Ragone, Carmen Manolio, Angela Mauriello, Franco M Buonaguro, Maria Lina Tornesello, Francesco Izzo, Alessandro Morabito, Sine Reker Hadrup, Maria Tagliamonte, Luigi Buonaguro
BACKGROUND: We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP). METHOD: A library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers...
March 20, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38504270/unveiling-cxcr2-as-a-promising-therapeutic-target-in-renal-cell-carcinoma-exploring-the-immunotherapeutic-paradigm-shift-through-its-inhibition-by-rct001
#9
JOURNAL ARTICLE
Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, Olivia Rastoin, Rosie Dawaliby, Thomas Schmitt, Maxence Bourgoin, Héliciane Palenzuela, Anne-Laure Rossi, Damien Ambrosetti, Jerome Durivault, Frederic Luciano, Delphine Borchiellini, Julie Le Du, Leticia Christina Pires Gonçalves, Patrick Auberger, Rachid Benhida, Lisa Kinget, Benoit Beuselinck, Cyril Ronco, Gilles Pagès, Maeva Dufies
BACKGROUND: In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40% success rate. Our study explored the potential of enhancing ccRCC treatment by concurrently using CXCR2 inhibitors alongside immunotherapies. METHODS: We analyzed ELR + CXCL levels and their correlation with patient survival during immunotherapy. RCT001, a unique CXCR2 inhibitor, was examined for its mechanism of action, particularly its effects on human primary macrophages...
March 19, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38500204/anaplastic-thyroid-cancer-spheroids-as-preclinical-models-to-test-therapeutics
#10
JOURNAL ARTICLE
Jiangnan Hu, Kaili Liu, Chandrayee Ghosh, Tejinder Pal Khaket, Helen Shih, Electron Kebebew
Anaplastic thyroid cancer (ATC) is the most aggressive thyroid cancer. Despite advances in tissue culture techniques, a robust model for ATC spheroid culture is yet to be developed. In this study, we created an efficient and cost-effective 3D tumor spheroids culture system from human ATC cells and existing cell lines that better mimic patient tumors and that can enhance our understanding of in vivo treatment response. We found that patient-derived ATC cells and cell lines can readily form spheroids in culture with a unique morphology, size, and cytoskeletal organization...
March 19, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38493157/the-localization-origin-and-impact-of-platelets-in-the-tumor-microenvironment-are-tumor-type-dependent
#11
JOURNAL ARTICLE
Ophélie Le Chapelain, Soumaya Jadoui, Angèle Gros, Samir Barbaria, Keltouma Benmeziane, Véronique Ollivier, Sébastien Dupont, Mialitiana Solo Nomenjanahary, Sabrina Mavouna, Jasmina Rogozarski, Marie-Anne Mawhin, Giuseppina Caligiuri, Sandrine Delbosc, Françoise Porteu, Bernhard Nieswandt, Pierre H Mangin, Yacine Boulaftali, Benoit Ho-Tin-Noé
BACKGROUND: How platelets interact with and influence the tumor microenvironment (TME) remains poorly characterized. METHODS: We compared the presence and participation of platelets in the TME of two tumors characterized by highly different TME, PyMT AT-3 mammary tumors and B16F1 melanoma. RESULTS: We show that whereas firmly adherent platelets continuously line tumor vessels of both AT-3 and B16F1 tumors, abundant extravascular stromal clusters of platelets from thrombopoietin-independent origin were present only in AT-3 mammary tumors...
March 16, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38493151/gli1-mediated-tumor-cell-derived-bfgf-promotes-tumor-angiogenesis-and-pericyte-coverage-in-non-small-cell-lung-cancer
#12
JOURNAL ARTICLE
Xueping Lei, Zhan Li, Manting Huang, Lijuan Huang, Yong Huang, Sha Lv, Weisong Zhang, Zhuowen Chen, Yuanyu Ke, Songpei Li, Jingfei Chen, Xiangyu Yang, Qiudi Deng, Junshan Liu, Xiyong Yu
BACKGROUND: Tumor angiogenesis inhibitors have been applied for non-small cell lung cancer (NSCLC) therapy. However, the drug resistance hinders their further development. Intercellular crosstalk between lung cancer cells and vascular cells was crucial for anti-angiogenenic resistance (AAD). However, the understanding of this crosstalk is still rudimentary. Our previous study showed that Glioma-associated oncogene 1 (Gli1) is a driver of NSCLC metastasis, but its role in lung cancer cell-vascular cell crosstalk remains unclear...
March 16, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38493133/blood-based-biomarkers-in-patients-with-non-small-cell-lung-cancer-treated-with-immune-checkpoint-blockade
#13
REVIEW
Yo-Ting Tsai, Jeffrey Schlom, Renee N Donahue
The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical responses observed among patients poses significant challenges. To date, analyses of tumor biopsies are the only parameter used to guide prognosis to ICI therapy. Tumor biopsies, however, are often difficult to obtain and tissue-based biomarkers are limited by intratumoral heterogeneity and temporal variability. In response, there has been a growing emphasis on the development of "liquid biopsy"‒ derived biomarkers, which offer a minimally invasive means to dynamically monitor the immune status of NSCLC patients either before and/or during the course of treatment...
March 16, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38486328/validation-of-a-multiomic-model-of-plasma-extracellular-vesicle-pd-l1-and-radiomics-for-prediction-of-response-to-immunotherapy-in-nsclc
#14
LETTER
Diego de Miguel-Perez, Murat Ak, Priyadarshini Mamindla, Alessandro Russo, Serafettin Zenkin, Nursima Ak, Vishal Peddagangireddy, Luis Lara-Mejia, Muthukumar Gunasekaran, Andres F Cardona, Aung Naing, Fred R Hirsch, Oscar Arrieta, Rivka R Colen, Christian Rolfo
BACKGROUND: Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to the lack of reliable predictive biomarkers. We showed preliminary data on the predictive role of the combination of radiomics and plasma extracellular vesicle (EV) PD-L1 to predict durable response to ICIs. MAIN BODY: Here, we validated this model in a prospective cohort of patients receiving ICIs plus chemotherapy and compared it with patients undergoing chemotherapy alone...
March 15, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38481346/correction-rna-binding-protein-rps7-promotes-hepatocellular-carcinoma-progression-via-loxl2-dependent-activation-of-itgb1-fak-src-signaling
#15
Yu-Jiao Zhou, Min-Li Yang, Xin He, Hui-Ying Gu, Ji-Hua Ren, Sheng-Tao Cheng, Zhou Fu, Zhen-Zhen Zhang, Juan Chen
No abstract text is available yet for this article.
March 14, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38475919/c-ebp%C3%AE-p30-confers-aml-cell-susceptibility-to-the-terminal-unfolded-protein-response-and-resistance-to-venetoclax-by-activating-ddit3-transcription
#16
JOURNAL ARTICLE
Mengbao Du, Mowang Wang, Meng Liu, Shan Fu, Yu Lin, Yankun Huo, Jian Yu, Xiaohong Yu, Chong Wang, Haowen Xiao, Limengmeng Wang
BACKGROUND: Acute myeloid leukemia (AML) with biallelic (CEBPAbi ) as well as single mutations located in the bZIP region is associated with a favorable prognosis, but the underlying mechanisms are still unclear. Here, we propose that two isoforms of C/EBPα regulate DNA damage-inducible transcript 3 (DDIT3) transcription in AML cells corporately, leading to altered susceptibility to endoplasmic reticulum (ER) stress and related drugs. METHODS: Human AML cell lines and murine myeloid precursor cell line 32Dcl3 cells were infected with recombinant lentiviruses to knock down CEBPA expression or over-express the two isoforms of C/EBPα...
March 13, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38475864/functionally-instructed-modifiers-of-response-to-atr-inhibition-in-experimental-glioma
#17
JOURNAL ARTICLE
Bianca Walter, Sophie Hirsch, Laurence Kuhlburger, Aaron Stahl, Leonard Schnabel, Silas Wisser, Lara A Haeusser, Foteini Tsiami, Sarah Plöger, Narges Aghaallaei, Advaita M Dick, Julia Skokowa, Christian Schmees, Markus Templin, Katja Schenke-Layland, Marcos Tatagiba, Sven Nahnsen, Daniel J Merk, Ghazaleh Tabatabai
BACKGROUND: The DNA damage response (DDR) is a physiological network preventing malignant transformation, e.g. by halting cell cycle progression upon DNA damage detection and promoting DNA repair. Glioblastoma are incurable primary tumors of the nervous system and DDR dysregulation contributes to acquired treatment resistance. Therefore, DDR targeting is a promising therapeutic anti-glioma strategy. Here, we investigated Ataxia telangiectasia and Rad3 related (ATR) inhibition (ATRi) and functionally-instructed combination therapies involving ATRi in experimental glioma...
March 12, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38468260/combined-il6-and-ccr2-blockade-potentiates-antitumor-activity-of-nk-cells-in-hpv-negative-head-and-neck-cancer
#18
JOURNAL ARTICLE
Fan Yang, Chenyang Yuan, Fanghui Chen, Zhaohui S Qin, Nicole C Schmitt, Gregory B Lesinski, Nabil F Saba, Yong Teng
BACKGROUND: While T cell-activating immunotherapies against recurrent head and neck squamous cell carcinoma (HNSCC) have shown impressive results in clinical trials, they are often ineffective in the majority of patients. NK cells are potential targets for immunotherapeutic intervention; however, the setback in monalizumab-based therapy in HNSCC highlights the need for an alternative treatment to enhance their antitumor activity. METHODS: Single-cell RNA sequencing (scRNA-seq) and TCGA HNSCC datasets were used to identify key molecular alterations in NK cells...
March 12, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38459559/trf2-as-novel-marker-of-tumor-response-to-taxane-based-therapy-from-mechanistic-insight-to-clinical-implication
#19
JOURNAL ARTICLE
Sara Iachettini, Irene Terrenato, Manuela Porru, Serena Di Vito, Angela Rizzo, Carmen D'Angelo, Eleonora Petti, Roberto Dinami, Carmen Maresca, Anna Di Benedetto, Aldo Palange, Antonino Mulè, Angela Santoro, Antonella Palazzo, Paola Fuso, Antonella Stoppacciaro, Patrizia Vici, Lorena Filomeno, Francesca Sofia Di Lisa, Teresa Arcuri, Eriseld Krasniqi, Alessandra Fabi, Annamaria Biroccio, Pasquale Zizza
BACKGROUND: Breast Cancer (BC) can be classified, due to its heterogeneity, into multiple subtypes that differ for prognosis and clinical management. Notably, triple negative breast cancer (TNBC) - the most aggressive BC form - is refractory to endocrine and most of the target therapies. In this view, taxane-based therapy still represents the elective strategy for the treatment of this tumor. However, due variability in patients' response, management of TNBC still represents an unmet medical need...
March 9, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38459595/a-glutamine-tug-of-war-between-cancer-and-immune-cells-recent-advances-in-unraveling-the-ongoing-battle
#20
REVIEW
Bolin Wang, Jinli Pei, Shengnan Xu, Jie Liu, Jinming Yu
Glutamine metabolism plays a pivotal role in cancer progression, immune cell function, and the modulation of the tumor microenvironment. Dysregulated glutamine metabolism has been implicated in cancer development and immune responses, supported by mounting evidence. Cancer cells heavily rely on glutamine as a critical nutrient for survival and proliferation, while immune cells require glutamine for activation and proliferation during immune reactions. This metabolic competition creates a dynamic tug-of-war between cancer and immune cells...
March 8, 2024: Journal of Experimental & Clinical Cancer Research: CR
journal
journal
28645
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.